Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
American Journal of Clinical Dermatology
Published in: American Journal of Clinical Dermatology 6/2020

01-12-2020 | Keloid | Review Article

Alternative Clinical Indications of Botulinum Toxin

Authors: Tina S. Alster, Iris S. Harrison

Published in: American Journal of Clinical Dermatology | Issue 6/2020

Login to get access

Abstract

Botulinum toxin type A (BoNTA) is a powerful neurotoxin that inhibits acetylcholine release from presynaptic vesicles. The potency and safety profile of BoNTA grant the toxin vast therapeutic potential. It has been used off-label for a variety of dermatologic conditions. This review aims to analyze published literature regarding the benefits and risks of the off-label use of BoNTA beyond facial lines, including eccrine hidrocystomas, enlarged pores, keloids and hypertrophic scars, hidradenitis suppurativa, hyperhidrosis, masseter muscle hypertrophy, and salivary gland hypertrophy, among others. A MEDLINE search from January 2000 to December 2019 was conducted on the off-label uses of botulinum toxin in dermatology.
Literature
1.
Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58–64.PubMed
2.
Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The Oxford 2011 levels of evidence. In: Oxford Centre for Evidence-Based Medicine.
3.
Wu CJ, Chang CK, Wang CY, Liao YS, Chen SG. Efficacy and safety of botulinum toxin A in axillary bromhidrosis and associated histological changes in sweat glands: a prospective randomized double-blind side-by-side comparison clinical study. Dermatol Surg. 2019;12:1605–9.
4.
Heckmann M, Teichmann B, Pause BM, Plewig G. Amelioration of body odor after intracutaneous axillary injection of botulinum toxin A. Arch Dermatol. 2003;139(1):57–9.PubMed
5.
He J, Wang T, Dong J. A close positive correlation between malodor and sweating as a marker for the treatment of axillary bromhidrosis with botulinum toxin A. J Dermatol Treat. 2012;23(6):461–4.
6.
He J, Wang T, Dong J. Effectiveness of botulinum toxin A injection for the treatment of secondary axillary bromhidrosis. J Plast Reconstr Aesthet Surg. 2017;70(11):1641–5.PubMed
7.
He J, Wang T, Dong J. A low initial botulinum toxin A treatment response does not predict poor long-term outcomes in patients with axillary bromhidrosis. J Dermatol Treat. 2018;29(1):102–4.
8.
Wang T, Dong J, He J. Long-term safety and efficacy of botulinum toxin A treatment in adolescent patients with axillary bromhidrosis. Aesthetic Plast Surg. 2018;42(2):560–4.PubMed
9.
Lee JB, Kim BS, Kim MB, Oh CK, Jang HS, Kwon KS. A case of foul genital odor treated with botulinum toxin A. Dermatol Surg. 2004;30(9):1233–5.PubMed
10.
Matarasso SL. Treatment of facial chromhidrosis with botulinum toxin type A. J Am Acad Dermatol. 2005;52(1):89–91.PubMed
11.
Wu JM, Mamelak AJ, Nussbaum R, McElgunn PS. Botulinum toxin A in the treatment of chromhidrosis. Dermatol Surg. 2005;31(8):963–5.PubMed
12.
Perez Tato B, Zamora Martinez E, Sanchez Albisua B, Perez Gonzalez YC, Polimon Olabarrieta I, Marinero Escobedo S, et al. Facial and axillary apocrine chromhidrosis. Dermatol Online J. 2012;18(3):13.PubMed
13.
Beer K, Oakley H. Axillary chromhidrosis: report of a case, review of the literature and treatment considerations. J Cosmet Dermatol. 2010;9(4):318–20.PubMed
14.
Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol. 2000;143(4):824–7.PubMed
15.
Sanli H, Ekmekci P, Akbostanci MC. Idiopathic localized crossed (left side of the upper part of the body, right side of the lower part of the body) hyperhidrosis: successful treatment of facial area with botulinum a toxin injection. Dermatol Surg. 2004;30(4):552–4.PubMed
16.
George SM, Atkinson LR, Farrant PB, Shergill BS. Botulinum toxin for focal hyperhidrosis of the face. Br J Dermatol. 2014;170(1):211–3.PubMed
17.
Komericki P, Ardjomand N. Hyperhidrosis of face and scalp: repeated successful treatment with botulinum toxin type A. Indian J Dermatol Venereol Leprol. 2012;78(2):201–2.PubMed
18.
Geddoa E, Balakumar AK, Paes TRF. The successful use of botulinum toxin for the treatment of nasal hyperhidrosis. Int J Dermatol. 2008;47(10):1079–80.PubMed
19.
Lera M, Espana A, Idoate MA. Focal hyperhidrosis secondary to eccrine naevus successfully treated with botulinum toxin type A. Clin Exp Dermatol. 2015;40(6):640–3.PubMed
20.
Nygaard U, Dalager S, Spaun E, Hedelund L. Large eccrine angiomatous hamartoma: a novel clinical presentation of disease. J Dermatol Case Rep. 2015;9(3):58–61.PubMedPubMedCentral
21.
Jansen S, Jerowski M, Ludwig L, Fischer-Krall E, Beutner D, Grosheva M. Botulinum toxin therapy in Frey's syndrome: a retrospective study of 440 treatments in 100 patients. Clin Otolaryngol. 2017;42(2):295–300.PubMed
22.
Gualberto GV, Sampaio FMS, Madureira NAB. Use of botulinum toxin type A in Frey's syndrome. An Bras Dermatol. 2017;92(6):891–2.PubMedPubMedCentral
23.
Freni F, Gazia F, Stagno d'Alcontres F, Galletti B, Galletti F. Use of botulinum toxin in Frey's syndrome. Clin Case Rep. 2019;7(3):482–5.PubMedPubMedCentral
24.
Henry N, Baker BG, Iyer S. Frey's syndrome following a facial burn treated with botulinum toxin. Ann Burns Fire Disasters. 2018;31(1):47–8.PubMedPubMedCentral
25.
Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg. 2007;33(8):924–7.PubMed
26.
Grazziotin TC, Buffon RB, da Silva Manzoni AP, Libis AS, Weber MB. Treatment of granulosis rubra nasi with botulinum toxin type A. Dermatol Surg. 2009;35(8):1298–9.PubMed
27.
Campanati A, Martina E, Giuliodori K, Bobyr I, Consales V, Offidani A. Two cases of hidradenitis suppurativa and botulinum toxin type a therapy: a novel approach for a pathology that is still difficult to manage. Dermatol Ther. 2019;32(3):12841.
28.
Khoo AB, Burova EP. Hidradenitis suppurativa treated with clostridium botulinum toxin A. Clin Exp Dermatol. 2014;39(6):749–50.PubMed
29.
Shi W, Schultz S, Strouse A, Gater DR. Successful treatment of stage III hidradenitis suppurativa with botulinum toxin A. BMJ Case Rep. 2019;12(1):e226064.PubMed
30.
O'Reilly DJ, Pleat JM, Richards AM. Treatment of hidradenitis suppurativa with botulinum toxin A. Plast Reconstr Surg. 2005;116(5):1575–6.PubMed
31.
Feito-Rodriguez M, Sendagorta-Cudos E, Herranz-Pinto P, de Lucas-Laguna R. Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A. Dermatol Surg. 2009;35(8):1300–2.PubMed
32.
Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22(4):431–6.PubMed
33.
Saber M, Brassard D, Benohanian A. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A. Arch Dermatol. 2011;147(5):629–30.PubMed
34.
Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology. 2001;57(11):2095–9.PubMed
35.
Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2002;28(9):822–7.PubMed
36.
Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of dysport vs. botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149(5):1041–5.PubMed
37.
Campanati A, Giuliodori K, Martina E, Giuliano A, Ganzetti G, Offidani A. Onabotulinumtoxin type A (botox) versus Incobotulinumtoxin type A (xeomin) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna). 2014;121(1):21–6.
38.
Mannava S, Mannava KA, Nazir OF, Plate JF, Smith BP, Koman LA, et al. Treatment of palmar hyperhidrosis with botulinum neurotoxin a. J Hand Surg Am. 2013;38(2):398–400.PubMed
39.
Kang A, Burns E, Glaser DA. Botulinum toxin A for palmar hyperhidrosis: associated pain, duration, and reasons for discontinuation of therapy. Dermatol Surg. 2015;41(2):297–8.PubMed
40.
Weinberg T, Solish N, Murray C. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatol Clin. 2014;32(4):505–15.PubMed
41.
Gregoriou S, Rigopoulos D, Makris M, Liakou A, Agiosofitou E, Stefanaki C, et al. Effects of botulinum toxin—a therapy for palmar hyperhidrosis in plantar sweat production. Dermatol Surg. 2010;36(4):496–8.PubMed
42.
Wollina U, Karamfilov T. Botulinum toxin A for palmar hyperhidrosis. J Eur Acad Dermatol Venereol. 2001;15(6):555–8.PubMed
43.
Lecouflet M, Leux C, Fenot M, Celerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary palmar hyperhidrosis: a study of 28 patients. J Am Acad Dermatol. 2014;70(6):1083–7.PubMed
44.
Vlahovic TC, Dunn SP, Blau JC, Gauthier C. Injectable botulinum toxin as a treatment for plantar hyperhidrosis: a case study. J Am Podiatr Med Assoc. 2008;98(2):156–9.PubMed
45.
Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol. 2007;17(1):52–4.PubMed
46.
Sevim S, Dogu O, Kaleagasi H. Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta Neurol Belg. 2002;102(4):167–70.PubMed
47.
Bernhard MK, Krause M, Syrbe S. Sweaty feet in adolescents-early use of botulinum type A toxin in juvenile plantar hyperhidrosis. Pediatr Dermatol. 2018;35(6):784–6.PubMed
48.
Swartling C, Naver H, Lindberg M, Anveden I. Treatment of dyshidrotic hand dermatitis with intradermal botulinum toxin. J Am Acad Dermatol. 2002;47(5):667–71.PubMed
49.
Wollina U, Karamfilov T. Adjuvant botulinum toxin A in dyshidrotic hand eczema: a controlled prospective pilot study with left-right comparison. J Eur Acad Dermatol Venereol. 2002;16(1):40–2.PubMed
50.
Kontochristopoulos G, Gregoriou S, Agiasofitou E, Nikolakis G, Rigopoulos D, Katsambas A. Regression of relapsing dyshidrotic eczema after treatment of concomitant hyperhidrosis with botulinum toxin-A. Dermatol Surg. 2007;33(10):1289–90.PubMed
51.
Pilkington SA, Bhome R, Welch RE, Ku F, Warden C, Harris S, et al. Bilateral versus unilateral botulinum toxin injections for chronic anal fissure: a randomised trial. Tech Coloproctol. 2018;22(7):545–51.PubMedPubMedCentral
52.
Berkel AE, Rosman C, Koop R, van Duijvendijk P, van der Palen J, Klaase JM. Isosorbide dinitrate ointment vs botulinum toxin A (dysport) as the primary treatment for chronic anal fissure: a randomized multicentre study. Colorectal Dis. 2014;16(10):360–6.
53.
Barbeiro S, Atalaia-Martins C, Marcos P, Goncalves C, Canhoto M, Arroja B, et al. Long-term outcomes of botulinum toxin in the treatment of chronic anal fissure: 5 years of follow-up. United Eur Gastroenterol J. 2017;5(2):293–7.
54.
Ravindran P, Chan DL, Ciampa C, George R, Punch G, White SI. High-dose versus low-dose botulinum toxin in anal fissure disease. Tech Coloproctol. 2017;21(10):803–8.PubMed
55.
Kavanagh GM, Tidman MJ. Botulinum A toxin and brachioradial pruritus. Br J Dermatol. 2012;166(5):1147.PubMed
56.
Jadhao VA, Lokhande N, Habbu SG, Sewane S, Dongare S, Goyal N. Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism. Indian J Dent Res. 2017;28(5):493–7.PubMed
57.
Guarda-Nardini L, Manfredini D, Salamone M, Salmaso L, Tonello S, Ferronato G. Efficacy of botulinum toxin in treating myofascial pain in bruxers: a controlled placebo pilot study. Cranio. 2008;26(2):126–35.PubMed
58.
Zhang LD, Liu Q, Zou DR, Yu LF. Occlusal force characteristics of masseteric muscles after intramuscular injection of botulinum toxin A (BTX-A) for treatment of temporomandibular disorder. Br J Oral Maxillofac Surg. 2016;54(7):736–40.PubMed
59.
Al-Wayli H. Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin A prospective and randomized clinical study. J Clin Exp Dent. 2017;9(1):112–7.
60.
Ondo WG, Simmons JH, Shahid MH, Hashem V, Hunter C, Jankovic J. Onabotulinum toxin-A injections for sleep bruxism: a double-blind, placebo-controlled study. Neurology. 2018;90(7):559–64.
61.
Lee SJ, McCall WD Jr, Kim YK, Chung SC, Chung JW. Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial. Am J Phys Med Rehabil. 2010;89(1):16–23.PubMed
62.
Akhtar N, Brooks P. The use of botulinum toxin in the management of burns itching: preliminary results. Burns. 2012;38(8):1119–23.PubMed
63.
Naik HB, Steinberg SM, Middelton LA, Hewitt SM, Zuo RC, Linehan WM, et al. Efficacy of intralesional botulinum toxin A for treatment of painful cutaneous leiomyomas: a randomized clinical trial. JAMA Dermatol. 2015;151(10):1096–102.PubMed
64.
Sifaki MK, Krueger-Krasagakis S, Koutsopoulos A, Evangelou GI, Tosca AD. Botulinum toxin type A: treatment of a patient with multiple cutaneous piloleiomyomas. Dermatology. 2009;218(1):44–7.PubMed
65.
Onder M, Adisen E. A new indication of botulinum toxin: leiomyoma-related pain. J Am Acad Dermatol. 2009;60(2):325–8.PubMed
66.
Helou J, Kechichian E, El Khoury R, Tomb R. Botulinum toxin injection: a novel treatment for erosive vulvitis. Dermatol Surg. 2017;43:363–5.
67.
Gonzalez-Ramos J, Alonso-Pacheco ML, Goiburu-Chenu B, Mayor-Ibarguren A, Herranz-Pinto P. Successful treatment of refractory pruritic Fox–Fordyce disease with botulinum toxin type A. Br J Dermatol. 2016;174(2):458–9.PubMed
68.
Norheim AJ, Mercer J, Musial F, de Weerd L. A new treatment for frostbite sequelae; botulinum toxin. Int J Circumpolar Health. 2017;76(1).
69.
Ravitskiy L, Heymann WR. Botulinum toxin-induced resolution of axillary granular parakeratosis. Skinmed. 2005;4(2):118–20.PubMed
70.
Gazerani P, Pedersen NS, Drewes AM, Arendt-Nielsen L. Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol. 2009;161(4):737–45.PubMed
71.
Heckmann M, Heyer G, Brunner B, Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. J Am Acad Dermatol. 2002;46(4):617–9.PubMed
72.
Schuler A, Veenstra J, Ozog D. Battling neuropathic scar pain with botulinum toxin. J Drugs Dermatol. 2019;18(9):937–8.PubMed
73.
DePry JL, Mann M. Successful treatment of postoperative pain after mohs micrographic surgery with onabotulinum toxin A. Dermatol Surg. 2017;43(12):1491–4.PubMed
74.
Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29(10):857–64.PubMed
75.
Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010;11(12):1827–33.PubMed
76.
Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–83.PubMed
77.
Ding XD, Zhong J, Liu YP, Chen HX. Botulinum as a toxin for treating post-herpetic neuralgia. Iran J Public Health. 2017;46(5):608–11.PubMedPubMedCentral
78.
Sotiriou E, Apalla Z, Panagiotidou D, Ioannidis D. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol. 2009;89(2):214–5.PubMed
79.
Bittar JM, Ditre C. Treatment of postherpetic neuralgia with botulinum toxin type A. J Am Acad Derm. 2019;81(4):AB140.
80.
Moon YE, Choi JH, Park HJ, Park JH, Kim JH. Ultrasound-guided nerve block with botulinum toxin type A for intractable neuropathic pain. Toxins (Basel). 2016;8(1):18.
81.
Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7(1):89–91.PubMed
82.
Li D, Xiao L. Combining botulinum toxin (A) injection with peripheral nerve stimulation in a patient for intractable ophthalmic postherpetic neuralgia. Neuromodulation. 2015;18(8):769–71.PubMed
83.
Jenkins SN, Neyman KM, Veledar E, Chen SC. A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon. J Am Acad Dermatol. 2013;69(5):834–5.PubMed
84.
Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, et al. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2016;43(1):56–62.PubMed
85.
Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma. J Hand Surg Eur. 2014;39(8):876–80.
86.
Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg Am. 2009;34(3):446–52.PubMed
87.
Neumeister MW. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am. 2010;35(12):2085–92.PubMed
88.
Van Beek AL, Lim PK, Gear AJ, Pritzker MR. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg. 2007;119(1):217–26.PubMed
89.
Zhang X, Hu Y, Nie Z, Song Y, Pan Y, Liu Y, et al. Treatment of Raynaud's phenomenon with botulinum toxin type A. Neurol Sci. 2015;36(7):1225–311.PubMed
90.
Medina S, Gomez-Zubiaur A, Valdeolivas-Casillas N, Polo-Rodriguez I, Ruiz L, Izquierdo C, et al. Botulinum toxin type A in the treatment of Raynaud's phenomenon: a three-year follow-up study. Eur J Rheumatol. 2018;5(4):224–9.PubMedPubMedCentral
91.
Kossintseva I, Barankin B. Improvement in both Raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. J Cutan Med Surg. 2008;12(4):189–93.PubMed
92.
Smith L, Polsky D, Franks AG Jr. Botulinum toxin-A for the treatment of Raynaud syndrome. Arch Dermatol. 2012;148(4):426–8.PubMed
93.
Sycha T, Graninger M, Auff E, Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Investig. 2004;34(4):312–3.
94.
Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, et al. The therapeutic efficacy of botulinum toxin in treating scleroderma-associated Raynaud's phenomenon: a randomized, double-blind, placebo-controlled clinical trial. Arthritis Rheumatol. 2017;69(8):1661–9.PubMedPubMedCentral
95.
Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM. Optimisation of botulinum toxin type A treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series. Clin Rheumatol. 2019;38(12):3669–766.PubMed
96.
97.
Garrido-Rios AA, Gonzalez-Olivares M, Navarro-Vidal B, Martinez-Moran C, Borbujo J. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin. Clin Exp Dermatol. 2018;43(4):503–5.PubMed
98.
Petersen CD, Giraldi A, Lundvall L, Kristensen E. Botulinum toxin type A-a novel treatment for provoked vestibulodynia? Results from a randomized, placebo controlled, double blinded study. J Sex Med. 2009;6(9):2523–37.PubMed
99.
Diomande I, Gabriel N, Kashiwagi M, Ghisu GP, Welter J, Fink D, et al. Subcutaneous botulinum toxin type A injections for provoked vestibulodynia: a randomized placebo-controlled trial and exploratory subanalysis. Arch Gynecol Obstet. 2019;299(4):993–1000.PubMed
100.
Hedebo Hansen T, Guldberg R, Meinert M. Botulinum toxin-treatment of localized provoked vulvodynia refractory to conventional treatment. Eur J Obstet Gynecol Reprod Biol. 2019;234:6–9.PubMed
101.
Jeon Y, Kim Y, Shim B, Yoon H, Park Y, Shim B, et al. A retrospective study of the management of vulvodynia. Korean J Urol. 2013;54(1):48–52.PubMedPubMedCentral
102.
Yoon H, Chung WS, Shim BS. Botulinum toxin A for the management of vulvodynia. Int J Impot Res. 2007;19(1):84–7.PubMed
103.
Pelletier F, Parratte B, Penz S, Moreno JP, Aubin F, Humbert P. Efficacy of high doses of botulinum toxin A for treating provoked vestibulodynia. Br J Dermatol. 2011;164(3):617–22.PubMed
104.
Tieu KD, MacGregor JL. Successful treatment of vulvodynia with botulinum toxin A. Arch Dermatol. 2011;147(2):251–2.PubMed
105.
Bobkiewicz A, Francuzik W, Krokowicz L, Studniarek A, Ledwosinski W, Paszkowski J, et al. Botulinum toxin injection for treatment of chronic anal fissure: is there any dose-dependent efficiency? A meta-analysis. World J Surg. 2016;40(12):3064–72.PubMedPubMedCentral
106.
107.
Becker-Wegerich PM, Rauch L, Ruzicka T. Botulinum toxin A: successful decollete rejuvenation. Dermatol Surg. 2002;28(2):168–71.PubMed
108.
Thomas AJ, Larson MO, Braden S, Cannon RB, Ward PD. Effect of 3 commercially available botulinum toxin neuromodulators on facial synkinesis: a randomized clinical trial. JAMA Facial Plast Surg. 2018;20(2):141–7.PubMed
109.
Shinn JR, Nwabueze NN, Du L, Patel PN, Motamedi KK, Norton C, et al. Treatment patterns and outcomes in botulinum therapy for patients with facial synkinesis. JAMA Facial Plast Surg. 2019;21(3):244–51.PubMedPubMedCentral
110.
Kim MJ, Kim JH, Cheon HI, Hur MS, Han SH, Lee YW, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019;45(9):1155–62.PubMed
111.
Dayan SH, Ashourian N, Cho K. A pilot, double-blind, placebo-controlled study to assess the efficacy and safety of incobotulinumtoxinA injections in the treatment of rosacea. J Drugs Dermatol. 2017;16(6):549–54.PubMed
112.
Odo ME, Odo LM, Farias RV, Primavera RA, Leao L, Cuce LC, et al. Botulinum toxin for the treatment of menopausal hot flushes: a pilot study. Dermatol Surg. 2011;37(11):1579–83.PubMed
113.
Park KY, Kwon HJ, Kim JM, Jeong GJ, Kim BJ, Seo SJ, et al. A pilot study to evaluate the efficacy and safety of treatment with botulinum toxin in patients with recalcitrant and persistent erythematotelangiectatic rosacea. Ann Dermatol. 2018;30(6):688–93.
114.
Eshghi G, Khezrian L, Alirezaei P. Botulinum toxin A in treatment of facial flushing. Acta Med Iran. 2016;54(7):454–7.PubMed
115.
Geddoa E, Matar HE, Paes TR. The use of botulinum toxin-A in the management of neck and anterior chest wall flushing: pilot study. Int J Dermatol. 2013;52(12):1547–50.PubMed
116.
Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015;41(Suppl 1):S9–16.PubMed
117.
Suh Y, Jeong GJ, Noh H, Sun S, Hwang CH, Oh TS, et al. A multicenter, randomized, open-label comparative study of prabotulinumtoxinA with two different dosages and diverse proportional injection styles for the reduction of gastrocnemius muscle hypertrophy in Asian women. Dermatol Ther. 2019;32(5):e13009.PubMed
118.
Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Vanadurongwan B, Lektrakul N. A pilot study comparing the efficacy of two formulations of botulinum toxin type A for muscular calves contouring. J Cosmet Dermatol. 2018;17(6):984–90.PubMed
119.
Bogari M, Tan A, Xin Y, Chai G, Lin L, Min P, et al. Treatment of gastrocnemius muscle hypertrophy with botulinum toxin injection followed by magnetic resonance imaging assessment and 3-dimensional evaluation. Aesthet Surg J. 2017;37(10):1146–56.PubMed
120.
Xu F, Ma H, Li Y, Cai J, Gu Z-C. Individualized treatment of botulinum toxin type A for hypertrophic muscular calves with different bulging units in asian women. Dermatol Surg. 2017;43:336–43.
121.
Lee HJ, Lee DW, Park YH, Cha MK, Kim HS, Ha SJ. Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg. 2004;30(6):867–71.PubMed
122.
Han KH, Joo YH, Moon SE, Kim KH. Botulinum toxin A treatment for contouring of the lower leg. J Dermatol Treat. 2006;17(4):250–4.
123.
Oh WJ, Kwon TR, Oh CT, Kim YS, Kim BJ. Clinical application of botulinum toxin A for calf hypertrophy followed by 3-dimensional computed tomography. Plast Reconstr Surg Glob Open. 2018;6(2):1071.
124.
Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. J Am Acad Dermatol. 2010;63(6):1042–51.PubMed
125.
Araujo JP, Cruz J, Oliveira JX, Canto AM. Botulinum toxin type-A as an alternative treatment for gummy smile: a case report. Dermatol Online J. 2018;24(7):20.
126.
Ghosn S, Uthman I, Dahdah M, Kibbi AG, Rubeiz N. Treatment of pachydermoperiostosis pachydermia with botulinum toxin type A. J Am Acad Dermatol. 2010;63(6):1036–41.PubMed
127.
Wei J, Xu H, Dong J, Li Q, Dai C. Prolonging the duration of masseter muscle reduction by adjusting the masticatory movements after the treatment of masseter muscle hypertrophy with botulinum toxin type A injection. Dermatol Surg. 2015;41:101–9.
128.
Shome D, Khare S, Kapoor R. Efficacy of botulinum toxin in treating Asian Indian patients with masseter hypertrophy: a 4-year follow-up study. Plast Reconstr Surg. 2019;144(3):390–6.
129.
Xie Y, Zhou J, Li H, Cheng C, Herrler T, Li Q. Classification of masseter hypertrophy for tailored botulinum toxin type A treatment. Plast Reconstr Surg. 2014;134(2):209–18.
130.
Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg. 2005;31(5):502–7 (discussion 7–8).
131.
Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg. 2003;29(5):477–83 (discussion 83).
132.
Kim HJ, Yum KW, Lee SS, Heo MS, Seo K. Effects of botulinum toxin type A on bilateral masseteric hypertrophy evaluated with computed tomographic measurement. Dermatol Surg. 2003;29(5):484–9.PubMed
133.
Lee JH, Park JH, Lee SK, Han KH, Kim SD, Yoon CS, et al. Efficacy and safety of incobotulinum toxin A in periocular rhytides and masseteric hypertrophy: side-by-side comparison with onabotulinum toxin A. J Dermatol Treat. 2014;25(4):326–30.
134.
Wanitphakdeedecha R, Ungaksornpairote C, Kaewkes A, Sathaworawong A, Lektrakul N, Manuskiatti W. The efficacy of two formulations of botulinum toxin type A for masseter reduction: a split-face comparison study. J Dermatol Treat. 2017;28(5):443–6.
135.
Nikolis A, Enright KM, Masouri S, Bernstein S, Antoniou C. Prospective evaluation of incobotulinumtoxinA in the management of the masseter using two different injection techniques. Clin Cosmet Investig Dermatol. 2018;11:347–56.PubMedPubMedCentral
136.
Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg. 2010;125(6):1693–705.PubMed
137.
Kim NH, Chung JH, Park RH, Park JB. The use of botulinum toxin type A in aesthetic mandibular contouring. Plast Reconstr Surg. 2005;115(3):919–30.PubMed
138.
von Lindern JJ, Niederhagen B, Appel T, Berge S, Reich RH. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg. 2001;107(2):327–32.
139.
Sayed KS, Hegazy R, Gawdat HI, Abdel Hay RM, Ahmed MM, Mohammed FN et al. The efficacy of intradermal injections of botulinum toxin in the management of enlarged facial pores and seborrhea: a split face-controlled study. J Dermatol Treat. 2020:1–7.
140.
Min P, Xi W, Grassetti L, Trisliana Perdanasari A, Torresetti M, Feng S, et al. Sebum production alteration after botulinum toxin type A injections for the treatment of forehead rhytides: a prospective randomized double-blind dose-comparative clinical investigation. Aesthet Surg J. 2015;35(5):600–10.PubMed
141.
Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013;39(3):443–8.PubMed
142.
Richards A, Ritz M, Donahoe S, Southwick G. Botox for contraction of pectoral muscles. Plast Reconstr Surg. 2001;108(1):270–1.PubMed
143.
Senior MA, Fourie LR. Botox and the management of pectoral spasm after subpectoral implant insertion. Plast Reconstr Surg. 2000;106(1):224–5.PubMed
144.
Bae GY, Yune YM, Seo K, Hwang SI. Botulinum toxin injection for salivary gland enlargement evaluated using computed tomographic volumetry. Dermatol Surg. 2013;39(9):1404–7.PubMed
145.
Scali C, Humphrey S, Jones D, Carruthers A. Treatment of posterior cheek enlargement in human immunodeficiency virus-positive individuals with botulinum toxin A. Dermatol Surg. 2013;39(9):1407–10.PubMed
146.
Hu L, Zou Y, Chang SJ, Qiu Y, Chen H, Gang M, et al. Effects of botulinum toxin on improving facial surgical scars: a prospective, split-scar, double-blind, randomized controlled trial. Plast Reconstr Surg. 2018;141(3):646–50.PubMed
147.
Lee SH, Min HJ, Kim YW, Cheon YW. The efficacy and safety of early postoperative botulinum toxin A injection for facial scars. Aesthetic Plast Surg. 2018;42(2):530–7.PubMed
148.
Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66(2):209–14.PubMed
149.
Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81(8):1023–8.PubMed
150.
Huang RL, Ho CK, Tremp M, Xie Y, Li Q, Zan T. Early postoperative application of botulinum toxin type A prevents hypertrophic scarring after epicanthoplasty: a split-face, double-blind, randomized trial. Plast Reconstr Surg. 2019;144(4):835–44.PubMed
151.
Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair. Plast Reconstr Surg. 2014;134(3):511–6.PubMed
152.
Navarro-Barquín D, Lozada-Hernández E, Tejeda-Hernández M, DeLeon-Jasso G, Morales-Rescalvo F, Flores-González E, et al. Use of the type A botulinum toxin in patients submitted to cheiloplasty to improve results in scarring in patients with nonsyndromic cleft lip and palate. Eur J Plast Surg. 2019;42(3):291–4.
153.
Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS ONE. 2014;9(12):e115690.PubMedPubMedCentral
154.
Kim YS, Lee HJ, Cho SH, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014;22(5):605–12.PubMed
155.
An MK, Cho EB, Park EJ, Kim KH, Kim LS, Kim KJ. Appropriate timing of early postoperative botulinum toxin type A injection for thyroidectomy scar management: a split-scar study. Plast Reconstr Surg. 2019;144(4):659–68.
156.
Phillips TJ, Fung E, Rigby MH, Burke E, Hart RD, Trites JRB, et al. The use of botulinum toxin type A in the healing of thyroidectomy wounds: a randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2019;143(2):375–81.
157.
Li YH, Yang J, Liu JQ, Xie ST, Zhang YJ, Zhang W, et al. A randomized, placebo-controlled, double-blind, prospective clinical trial of botulinum toxin type A in prevention of hypertrophic scar development in median sternotomy wound. Aesthetic Plast Surg. 2018;42(5):1364–9.PubMed
158.
Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015;14(2):161–6.PubMed
159.
Pruksapong C, Yingtaweesittikul S, Burusapat C. Efficacy of botulinum toxin A in preventing recurrence keloids: double blinded randomized controlled trial study: intraindividual subject. J Med Assoc Thai. 2017;100(3):280–6.PubMed
160.
Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg. 2009;124(5):275–7.
161.
Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012;25(6):313–8.PubMed
162.
Robinson AJ, Khadim MF, Khan K. Keloid scars and treatment with botulinum toxin type A: the belfast experience. J Plast Reconstr Aesthet Surg. 2013;66(3):439–40.PubMed
163.
Uyesugi B, Lippincott B, Dave S. Treatment of a painful keloid with botulinum toxin type A. Am J Phys Med Rehabil. 2010;89(2):153–5.PubMed
164.
Elhefnawy AM. Assessment of intralesional injection of botulinum toxin type A injection for hypertrophic scars. Indian J Dermatol Venereol Leprol. 2016;82(3):279–83.PubMed
165.
Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33(3):409–12.PubMed
166.
Jung GS. Temporalis muscle reduction using botulinum toxin type A for a desirable upper face circumference. Facial Plast Surg. 2019;35(5):559–60.PubMed
167.
Zhou R-R, Wu H-L, Zhang X-D, Ye L-L, Shao H-J, Song X-H, et al. Efficacy and safety of botulinum toxin type A injection in patients with bilateral trapezius hypertrophy. Aesthetic Plast Surg. 2018;42(6):1664–711.PubMed
168.
Jeong SY, Park KY, Seok J, Ko EJ, Kim TY, Kim BJ. Botulinum toxin injection for contouring shoulder. J Eur Acad Dermatol Venereol. 2017;31(1):46–7.
169.
Austin E, Koo E, Jagdeo J. The cellular response of keloids and hypertrophic scars to botulinum toxin A: a comprehensive literature Review. Dermatol Surg. 2018;44(2):149–57.PubMed
170.
Yu P, Yang X, Qi Z. The use of botulinum toxin type A in the healing of thyroidectomy wounds: a randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2020;145(1):211.
171.
Guo X, Jin X. The use of botulinum toxin type A in the healing of thyroidectomy wounds: A randomized, prospective, placebo-controlled study. Plast Reconstr Surg. 2019;144(6):1125.
172.
Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional injection of botulinum toxin type A compared with intralesional injection of corticosteroid for the treatment of hypertrophic scar and keloid: a systematic review and meta-analysis. Med Sci Monit. 2019;25:2950–8.PubMedPubMedCentral
173.
Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246–8.
174.
Singh S, Neema S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg. 2017;10(3):163–7.PubMedPubMedCentral
175.
Zhang L, Yu Q, Wang Y, Ma Y, Shi Y, Li X. A small dose of botulinum toxin A is effective for treating androgenetic alopecia in Chinese patients. Dermatol Ther. 2019;32(4):12785.
176.
Cutrer FM, Pittelkow MR. Cephalalgic alopecia areata: a syndrome of neuralgiform head pain and hair loss responsive to botulinum A toxin injection. Cephalalgia. 2006;26(6):747–51.PubMed
177.
Irimia P, Palma JA, Idoate MA, Espana A, Riverol M, Martinez-Vila E. Cephalalgia alopecia or nummular headache with trophic changes? A new case with prolonged follow-up. Headache. 2013;53(6):994–7.PubMed
178.
Tamura BM, Sortino-Rachou AM, Cuce LC. Folliculitis responds to botulinum toxin: is it possible? Dermatol Surg. 2007;33(11):1398–400.PubMed
179.
Hyun MY, Kim BJ, Lee C, Kim JW. Radiation-induced alopecia treated with botulinum toxin type A injection. Plast Reconstr Surg Glob Open. 2014;2(10):226.
180.
Cutrer FM, Sandroni P, Wendelschafer-Crabb G. Botulinum toxin treatment of cephalalgia alopecia increases substance P and calcitonin gene-related peptide-containing cutaneous nerves in scalp. Cephalalgia. 2010;30(8):1000–6.PubMed
181.
Bordelon JR, Tang N, Elston D, Niedt G, Lazic ST. Multiple apocrine hidrocystomas successfully treated with botulinum toxin A. Br J Dermatol. 2017;176(2):488–90.PubMed
182.
Houle MC, Al Dhaybi R, Benohanian A. Unilateral aquagenic keratoderma treated with botulinum toxin A. J Dermatol Case Rep. 2010;4(1):1–5.PubMedPubMedCentral
183.
Diba VC, Cormack GC, Burrows NP. Botulinum toxin is helpful in aquagenic palmoplantar keratoderma. Br J Dermatol. 2005;152(2):394–5.PubMed
184.
María GC, Carmen DM, Cristina MFL. Use of botulinum toxin in the treatment of aquagenic keratoderma: one case report. Dermatol Ther. 2018;31(5):e12689.
185.
Bagazgoitia L, Perez-Carmona L, Salguero I, Harto A, Jaen P. Aquagenic keratoderma: successful treatment with botulinum toxin. Dermatol Surg. 2010;36(3):434–6.PubMed
186.
Kontochristopoulos G, Katsavou AN, Kalogirou O, Agelidis S, Zakopoulou N. Botulinum toxin type A: an alternative symptomatic management of Darier's disease. Dermatol Surg. 2007;33(7):882–3.PubMed
187.
Santiago-et-Sanchez-Mateos JL, Bea S, Fernandez M, Perez B, Harto A, Jaen P. Botulinum toxin type A for the preventive treatment of intertrigo in a patient with Darier's disease and inguinal hyperhidrosis. Dermatol Surg. 2008;34(12):1733–7.PubMed
188.
Ossorio-García L, Collantes-Rodríguez C, Villegas-Romero I, Linares-Barrios M. Vegetating Darier disease treated with botulinum toxin. JAMA Dermatol. 2018;154(1):106–8.PubMed
189.
Ebrahimi A, Radmanesh M. Botulinum toxin type-A (BT-A) for the treatment of multiple eccrine hydrocystomas. J Dermatol Treat. 2010;21(2):80–2.
190.
Gheisari M, Hamedani B, Robati R, Mozafari N. Intralesional botulinum toxin-A injection for the treatment of multiple eccrine hidrocystomas. J Cosmet Laser Ther. 2018;20(5):287–92.PubMed
191.
Blugerman G, Schavelzon D, D'Angelo S. Multiple eccrine hidrocystomas: a new therapeutic option with botulinum toxin. Dermatol Surg. 2003;29(5):557–9.PubMed
192.
Kontochristopoulos G, Markantoni V, Stefanaki C, Kanelleas A, Rigopoulos D, Gregoriou S. Multiple eccrine hidrocystomas treated with botulinum toxin A. Clin Exp Dermatol. 2011;36(1):95–6.PubMed
193.
Meys R, Perrett CM. Treatment of multiple periocular eccrine hidrocystomata: is botulinum toxin or electrocautery more effective? Clin Exp Dermatol. 2015;40(1):101–3.PubMed
194.
Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol. 2010;163(5):1072–6.PubMed
195.
Abitbol RJ, Zhou LH. Treatment of epidermolysis bullosa simplex, Weber–Cockayne type, with botulinum toxin type A. Arch Dermatol. 2009;145(1):13–5.PubMed
196.
Kothapalli A, Caccetta T. Botulinum toxin type A for the first-line treatment of Hailey-–Hailey disease. Australas J Dermatol. 2019;60(1):73–4.PubMed
197.
Bessa GR, Grazziotin TC, Manzoni AP, Weber MB, Bonamigo RR. Hailey-Hailey disease treatment with botulinum toxin type A. An Bras Dermatol. 2010;85(5):717–22.PubMed
198.
Charlton OA, Stewart TJ, Rosen RH. Treatment of Hailey-Hailey disease with botulinum toxin. Australas J Dermatol. 2018;59(3):229–31.PubMed
199.
Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A. Botulinum toxin type A for the treatment of axillary Hailey–Hailey disease. Dermatol Surg. 2000;26(4):371–4.PubMed
200.
Ho D, Jagdeo J. Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey–Hailey disease. J Drugs Dermatol. 2015;14(1):68–70.PubMed
201.
Kang NG, Yoon TJ, Kim TH. Botulinum toxin type A as an effective adjuvant therapy for Hailey–Hailey disease. Dermatol Surg. 2002;28(6):543.PubMed
202.
Koeyers WJ, Van Der Geer S, Krekels G. Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey–Hailey disease. J Dermatol Treat. 2008;19(4):251–4.
203.
Bedi M, Taylor AL. Recalcitrant Hailey–Hailey disease responds to oral tacrolimus and botulinum toxin type A. Cutis. 2015;96(6):14–6.
204.
Konrad H, Karamfilov T, Wollina U. Intracutaneous botulinum toxin A versus ablative therapy of Hailey–Hailey disease–a case report. J Cosmet Laser Ther. 2001;3(4):181–4.PubMed
205.
Legendre L, Maza A, Almalki A, Bulai-Livideanu C, Paul C, Mazereeuw-Hautier J. Botulinum toxin A: an effective treatment for linear immunoglobulin A bullous dermatosis located in the axillae. Acta Derm Venereol. 2016;96(1):122–3.PubMed
206.
Todberg T, Zachariae C, Bregnhoj A, Hedelund L, Bonefeld KK, Nielsen K, et al. The effect of botulinum neurotoxin A in patients with plaque psoriasis—an exploratory trial. J Eur Acad Dermatol Venereol. 2018;32(2):81–2.
207.
Aschenbeck KA, Hordinsky MK, Kennedy WR, Wendelschafer-Crabb G, Ericson ME, Kavand S, et al. Neuromodulatory treatment of recalcitrant plaque psoriasis with onabotulinumtoxinA. J Am Acad Dermatol. 2018;79(6):1156–9.PubMed
208.
Gilbert E, Ward NL. Efficacy of botulinum neurotoxin type A for treating recalcitrant plaque psoriasis. J Drugs Dermatol. 2014;13(11):1407–8.PubMed
209.
Koren A, Sprecher E, Reider E, Artzi O. A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma. Br J Dermatol. 2019.
210.
Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol. 2006;154(4):763–5.PubMed
211.
Gonzalez-Ramos J, Sendagorta-Cudos E, Gonzalez-Lopez G, Mayor-Ibarguren A, Feltes-Ochoa R, Herranz-Pinto P. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther. 2016;29(1):32–6.PubMed
212.
Durand PD, Couto RA, Isakov R, Yoo DB, Azizzadeh B, Guyuron B, et al. Botulinum toxin and muscle atrophy: a wanted or unwanted effect. Aesthet Surg J. 2016;36(4):482–7.PubMed
213.
Peng HP, Peng JH. Complications of botulinum toxin injection for masseter hypertrophy: incidence rate from 2036 treatments and summary of causes and preventions. J Cosmet Dermatol. 2018;17(1):33–8.PubMed
214.
Kim KS, Byun YS, Kim YJ, Kim ST. Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle. Dermatol Surg. 2009;35(12):1902–6.PubMed
215.
Wollina U, Konrad H. Managing adverse events associated with botulinum toxin type A. Am J Clin Dermatol. 2012;6(3):141–50.
216.
Fortuna R, Vaz MA, Youssef AR, Longino D, Herzog W. Changes in contractile properties of muscles receiving repeat injections of botulinum toxin (Botox). J Biomech. 2011;44(1):39–44.PubMed
217.
Salari M, Sharma S, Jog MS. Botulinum toxin induced atrophy: an uncharted territory. Toxins (Basel). 2018;10(8):313.
218.
Bellows S, Jankovic J. Immunogenicity associated with botulinum toxin treatment. Toxins (Basel). 2019;11(9).
219.
Li M, Goldberger BA, Hopkins C. Fatal case of botox-related anaphylaxis? J Forensic Sci. 2005;50(1):169–72.PubMed
220.
Moon IJ, Chang SE, Kim SD. First case of anaphylaxis after botulinum toxin type A injection. Clin Exp Dermatol. 2017;42(7):760–2.PubMed
221.
Pickett A. Can botulinum toxin cause anaphylaxis after an aesthetic treatment? Clin Exp Dermatol. 2018;43(5):599–600.PubMed
222.
Pickett A, Mewies M. Serious issues relating to the clinical use of unlicensed botulinum toxin products. J Am Acad Dermatol. 2009;61(1):149–50.PubMed
Metadata
Title
Alternative Clinical Indications of Botulinum Toxin
Authors
Tina S. Alster
Iris S. Harrison
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
American Journal of Clinical Dermatology / Issue 6/2020
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI
https://doi.org/10.1007/s40257-020-00532-0

Other articles of this Issue 6/2020

American Journal of Clinical Dermatology 6/2020 Go to the issue

Review Article

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review

Leading Article

Novel Therapies for Pemphigus Vulgaris

Current Opinion

BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors

Review Article

Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors

Original Research Article

The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris

Acknowledgement to Referees

Acknowledgement to Referees